---
document_datetime: 2025-11-23 13:09:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pramipexole-teva.html
document_name: pramipexole-teva.html
version: success
processing_time: 0.1315678
conversion_datetime: 2025-12-23 23:40:12.958954
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pramipexole Teva

[RSS](/en/individual-human-medicine.xml/66111)

##### Authorised

This medicine is authorised for use in the European Union

pramipexole

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Pramipexole Teva](#more-information-on-pramipexole-teva-1204)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Pramipexole Teva?

Pramipexole Teva is a medicine containing the active substance pramipexole base. It is available as white, round tablets (0.088, 0.18, 0.35 and 0.7 mg).

Pramipexole Teva is a 'generic medicine'. This means that Pramipexole Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called Sifrol.

## What is Pramipexole Teva used for?

Pramipexole Teva is used to treat the symptoms of Parkinson's disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness. Pramipexole Teva can be used either on its own or in combination with levodopa (another medicine for Parkinson's disease), at any stage of disease including the later stages when levodopa starts becoming less effective.

The medicine can only be obtained with a prescription.

## How is Pramipexole Teva used?

Pramipexole Teva tablets should be swallowed with water, with or without food. The starting dose is 0.088 mg three times per day. The dose should be increased every five to seven days until symptoms are controlled without causing side effects that cannot be tolerated. The maximum daily dose is 1.1 mg three times per day. Pramipexole Teva must be given less frequently in patients who have problems with their kidneys. If treatment is stopped for any reason, the dose should be decreased gradually.

For more information, see the package leaflet.

## How does Pramipexole Teva work?

The active substance in Pramipexole Teva, pramipexole, is a dopamine agonist, which imitates the action of dopamine. Dopamine is a messenger substance in the parts of the brain that control movement and coordination. In patients with Parkinson's disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases. The patients then lose their ability to control their movements reliably. Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson's disease, such as shaking, stiffness and slowness of movement.

## How has Pramipexole Teva been studied?

Because Pramipexole Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (i.e. that the two medicines produce the same levels of the active substance in the body).

## What are the benefit and risk of Pramipexole Teva?

Because Pramipexole Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.

## Why has Pramipexole Teva been approved?

The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pramipexole Teva has been shown to have comparable quality and to be bioequivalent to Sifrol. Therefore, the CHMP's view was that, as for Sifrol, the benefit outweighs the identified risk. The Committee recommended that Pramipexole Teva be given marketing authorisation.

## Other information about Pramipexole Teva

The European Commission granted a marketing authorisation valid throughout the EU for Pramipexole Teva to Teva Pharma B.V. on 18 December 2008.

Pramipexole Teva : EPAR - Summary for the public

English (EN) (39.17 KB - PDF)

**First published:** 10/03/2009

[View](/en/documents/overview/pramipexole-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-716)

български (BG) (163.77 KB - PDF)

**First published:**

10/03/2009

[View](/bg/documents/overview/pramipexole-teva-epar-summary-public_bg.pdf)

español (ES) (39.78 KB - PDF)

**First published:**

10/03/2009

[View](/es/documents/overview/pramipexole-teva-epar-summary-public_es.pdf)

čeština (CS) (152.63 KB - PDF)

**First published:**

10/03/2009

[View](/cs/documents/overview/pramipexole-teva-epar-summary-public_cs.pdf)

dansk (DA) (39.4 KB - PDF)

**First published:**

10/03/2009

[View](/da/documents/overview/pramipexole-teva-epar-summary-public_da.pdf)

Deutsch (DE) (40.02 KB - PDF)

**First published:**

10/03/2009

[View](/de/documents/overview/pramipexole-teva-epar-summary-public_de.pdf)

eesti keel (ET) (39.14 KB - PDF)

**First published:**

10/03/2009

[View](/et/documents/overview/pramipexole-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (158.33 KB - PDF)

**First published:**

10/03/2009

[View](/el/documents/overview/pramipexole-teva-epar-summary-public_el.pdf)

français (FR) (40.19 KB - PDF)

**First published:**

10/03/2009

[View](/fr/documents/overview/pramipexole-teva-epar-summary-public_fr.pdf)

italiano (IT) (39.66 KB - PDF)

**First published:**

10/03/2009

[View](/it/documents/overview/pramipexole-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (151.44 KB - PDF)

**First published:**

10/03/2009

[View](/lv/documents/overview/pramipexole-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (149.41 KB - PDF)

**First published:**

10/03/2009

[View](/lt/documents/overview/pramipexole-teva-epar-summary-public_lt.pdf)

magyar (HU) (147.07 KB - PDF)

**First published:**

10/03/2009

[View](/hu/documents/overview/pramipexole-teva-epar-summary-public_hu.pdf)

Malti (MT) (154.65 KB - PDF)

**First published:**

10/03/2009

[View](/mt/documents/overview/pramipexole-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (39.61 KB - PDF)

**First published:**

10/03/2009

[View](/nl/documents/overview/pramipexole-teva-epar-summary-public_nl.pdf)

polski (PL) (161.55 KB - PDF)

**First published:**

10/03/2009

[View](/pl/documents/overview/pramipexole-teva-epar-summary-public_pl.pdf)

português (PT) (39.83 KB - PDF)

**First published:**

10/03/2009

[View](/pt/documents/overview/pramipexole-teva-epar-summary-public_pt.pdf)

română (RO) (144.92 KB - PDF)

**First published:**

10/03/2009

[View](/ro/documents/overview/pramipexole-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (149.99 KB - PDF)

**First published:**

10/03/2009

[View](/sk/documents/overview/pramipexole-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (143.64 KB - PDF)

**First published:**

10/03/2009

[View](/sl/documents/overview/pramipexole-teva-epar-summary-public_sl.pdf)

Suomi (FI) (39.4 KB - PDF)

**First published:**

10/03/2009

[View](/fi/documents/overview/pramipexole-teva-epar-summary-public_fi.pdf)

svenska (SV) (39.25 KB - PDF)

**First published:**

10/03/2009

[View](/sv/documents/overview/pramipexole-teva-epar-summary-public_sv.pdf)

## Product information

Pramipexole Teva : EPAR - Product Information

English (EN) (577.83 KB - PDF)

**First published:** 28/08/2009

**Last updated:** 02/09/2024

[View](/en/documents/product-information/pramipexole-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-688)

български (BG) (732.58 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/bg/documents/product-information/pramipexole-teva-epar-product-information_bg.pdf)

español (ES) (650.21 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/es/documents/product-information/pramipexole-teva-epar-product-information_es.pdf)

čeština (CS) (668.21 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/cs/documents/product-information/pramipexole-teva-epar-product-information_cs.pdf)

dansk (DA) (634.7 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/da/documents/product-information/pramipexole-teva-epar-product-information_da.pdf)

Deutsch (DE) (641.63 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/de/documents/product-information/pramipexole-teva-epar-product-information_de.pdf)

eesti keel (ET) (665.77 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/et/documents/product-information/pramipexole-teva-epar-product-information_et.pdf)

ελληνικά (EL) (776.58 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/el/documents/product-information/pramipexole-teva-epar-product-information_el.pdf)

français (FR) (655.32 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/fr/documents/product-information/pramipexole-teva-epar-product-information_fr.pdf)

hrvatski (HR) (634.48 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/hr/documents/product-information/pramipexole-teva-epar-product-information_hr.pdf)

íslenska (IS) (648.47 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/is/documents/product-information/pramipexole-teva-epar-product-information_is.pdf)

italiano (IT) (595.63 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/it/documents/product-information/pramipexole-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (717.97 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/lv/documents/product-information/pramipexole-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (663.09 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/lt/documents/product-information/pramipexole-teva-epar-product-information_lt.pdf)

magyar (HU) (730.06 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/hu/documents/product-information/pramipexole-teva-epar-product-information_hu.pdf)

Malti (MT) (704.93 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/mt/documents/product-information/pramipexole-teva-epar-product-information_mt.pdf)

Nederlands (NL) (600.34 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/nl/documents/product-information/pramipexole-teva-epar-product-information_nl.pdf)

norsk (NO) (631.68 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/no/documents/product-information/pramipexole-teva-epar-product-information_no.pdf)

polski (PL) (704.32 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/pl/documents/product-information/pramipexole-teva-epar-product-information_pl.pdf)

português (PT) (575.31 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/pt/documents/product-information/pramipexole-teva-epar-product-information_pt.pdf)

română (RO) (716.3 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/ro/documents/product-information/pramipexole-teva-epar-product-information_ro.pdf)

slovenčina (SK) (658.68 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/sk/documents/product-information/pramipexole-teva-epar-product-information_sk.pdf)

slovenščina (SL) (704.88 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/sl/documents/product-information/pramipexole-teva-epar-product-information_sl.pdf)

Suomi (FI) (647.51 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/fi/documents/product-information/pramipexole-teva-epar-product-information_fi.pdf)

svenska (SV) (572.01 KB - PDF)

**First published:**

28/08/2009

**Last updated:**

02/09/2024

[View](/sv/documents/product-information/pramipexole-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0057 29/08/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pramipexole Teva : EPAR - All Authorised presentations

English (EN) (14.16 KB - PDF)

**First published:** 10/03/2009

**Last updated:** 17/08/2020

[View](/en/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-299)

български (BG) (39.3 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/bg/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (15.85 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/es/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.26 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/cs/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (13.94 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/da/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.06 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/de/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.55 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/et/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.54 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/el/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (17.06 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/fr/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (32.64 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/hr/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.71 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/is/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (15.01 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/it/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (34.8 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/lv/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (37.32 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/lt/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (32.48 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/hu/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.44 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/mt/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.61 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/nl/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (15.86 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/no/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (24.95 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/pl/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.06 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/pt/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (36.48 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/ro/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (22.86 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/sk/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (22.06 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/sl/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (15.35 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/fi/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.33 KB - PDF)

**First published:**

10/03/2009

**Last updated:**

17/08/2020

[View](/sv/documents/all-authorised-presentations/pramipexole-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pramipexole Teva Active substance pramipexole dihydrochloride monohydrate International non-proprietary name (INN) or common name pramipexole Therapeutic area (MeSH) Parkinson Disease Anatomical therapeutic chemical (ATC) code N04BC05

### Pharmacotherapeutic group

Anti-Parkinson drugs

### Therapeutic indication

Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).

Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).

## Authorisation details

EMA product number EMEA/H/C/000940

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva Pharma B.V.

Computerweg 10

Opinion adopted 23/10/2008 Marketing authorisation issued 18/12/2008 Revision 24

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pramipexole Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (174.4 KB - PDF)

**First published:** 28/08/2009

**Last updated:** 02/09/2024

[View](/en/documents/procedural-steps-after/pramipexole-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pramipexole Teva : EPAR - Public assessment report

English (EN) (199.02 KB - PDF)

**First published:** 10/03/2009

**Last updated:** 10/03/2009

[View](/en/documents/assessment-report/pramipexole-teva-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Pramipexole Teva

English (EN) (32.93 KB - PDF)

**First published:** 23/10/2008

**Last updated:** 23/10/2008

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-pramipexole-teva_en.pdf)

#### More information on Pramipexole Teva

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/09/2024

## Share this page

[Back to top](#main-content)